Daniel Rios Pinto Ribeiro, Eduardo Cambruzzi, Juliana Canedo Sebben, Karina Pezzi Melleu, Mareia Moura Schmidt, Carlos AM Gottschall, Alexandre Schaan de Quadros
ALTITUDE: Aliskiren Trial In Type 2 Diabetes Using Cardio Renal Endpoints.
Editorial Comment: Morbimortality in diabetic patients is still a matter of deep concern in the context of reduced cardiovascular mortality of recent years. Based on the proven clinical benefit of drugs such as ACEIs or ARBs in treating patients with renal failure, the study randomized 8700 treated with aliskiren or placebo, in a 32 month<a href="https://solaci.org/en/2015/06/24/congress-item-7126/" title="Read more" >...</a>
EXAMINE: The alogliptin is safe for treating type 2 diabetes in patients with a recent history of acute coronary syndrome.
Type 2 diabetes is associated both microvascular and macrovascular disease. Adequate glycemic control can reduce the risk of many microvascular complications but have not shown the same effect on macrovascular complications. This study evaluates the results of alogliptin compared with placebo in patients with type 2 diabetes who had a recent acute coronary syndrome. The<a href="https://solaci.org/en/2015/06/24/congress-item-5369/" title="Read more" >...</a>
Gastric bypass puts type 2 diabetes into remission
Original title: Effects of Ingestion Routes on Hormonal and Metabolic Profiles in Gastric-Bypassed Humans. Reference: Andreas Lindqvist, Peter Spégel, Mikael Ekelund, Hindrik Mulder, Leif Groop, Jan Hedenbro and Nils Wierup. . JCEM, 2013 DOI: 10.1210/jc.2012-3996. A team of researchers at Lund University has explained why gastric bypass often sends diabetes to fast remission, which could be a step<a href="https://solaci.org/en/2013/06/13/n-2633/" title="Read more" >...</a>
EXCEL Study: Complete vs. Incomplete Revascularization
Regardless of whether it is attempted through percutaneous coronary intervention (PCI) or myocardial revascularization surgery (MRS), complete revascularization (CR) is not always achieved. Overall, it is more frequent with surgery than with percutaneous treatment. Additionally, incomplete revascularization (IR) has proven to be associated with worse outcomes compared to CR. Researchers conducted an analysis of the<a href="https://solaci.org/en/2024/04/24/excel-study-complete-vs-incomplete-revascularization/" title="Read more" >...</a>
Peripheral Vascular Disease: Our Reality in Latin America, with the LATAM SOLACI Peripheral Registry
On the one hand, chronic peripheral vascular disease is on the rise. On the other, over the past 20 years, percutaneous coronary intervention (PCI) has gained considerable ground thanks to various new devices, replacing surgery as an alternative in most scenarios. Both strategies have shown similar results, but PCI has fewer complications and shorter hospital stays.<a href="https://solaci.org/en/2024/04/18/peripheral-vascular-disease-our-reality-in-latin-america-with-the-latam-solaci-peripheral-registry/" title="Read more" >...</a>
ACC 2024 | DEDICATE Trial: Transcatheter or Surgical Treatment of Aortic Valve Stenosis
In recent years, TAVR has been increasingly used; however, when it comes to younger, lower risk patients, its use is still challenged. In this context, there is limited information and we lack randomized studies on “real world” cohorts. The DEDICATE randomized 1.414 patients over 65 with severe symptomatic aortic stenosis. 701 of these patients received<a href="https://solaci.org/en/2024/04/11/acc-2024-dedicate-trial-transcatheter-or-surgical-treatment-of-aortic-valve-stenosis/" title="Read more" >...</a>
ACC 2024 | ULTIMATE-DAPT Trial
The international guidelines recommend the use of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor during 12 months in patients receiving percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), to prevent events such as MI and stent thrombosis. This was a multicenter, placebo controlled, double blind study to determine whether ticagrelor alone,<a href="https://solaci.org/en/2024/04/10/acc-2024-ultimate-dapt-trial/" title="Read more" >...</a>
ACC 2024 | RELIEVE-HF
Heart failure is characterized by increased left atrial filling pressure and venous congestion which intensify with exercise and volume burden, and makes conventional medical management hard. In this context, interatrial shunting might offer a self-regulating mechanism, as shown by the Ventura IAS study. The aim of this study was to assess the safety and efficacy<a href="https://solaci.org/en/2024/04/10/acc-2024-relieve-hf/" title="Read more" >...</a>